Neville M E, Hiserodt J C
J Immunol. 1982 Mar;128(3):1246-51.
Xenogeneic antiserum (RH1) was prepared in Lewis rats by hyperimmunization with concanavalin A- (Con A) activated alloimmune human lymphocytes. The antiserum RH1 effectively inhibited human antibody-dependent cellular cytotoxicity (ADCC), cell-mediated cytotoxicity (CMC), and natural killing (NK) in the absence of complement (C). Inhibition by RH1 was dependent on the dilution of antiserum employed and the number of cytotoxic lymphocytes present during cytolysis. Pretreatment of lymphocytes with RH1 or the presence of RH1 in culture did not inhibit lymphocyte proliferation stimulated by Con A, phytohemagglutinin, or allogeneic cells; lymphokine production as measured by leukocyte-inhibiting factor production; antibody-dependent C lysis; or CMC mediated by murine cytotoxic T lymphocytes. Analysis of the mechanism of inhibition of cytotoxicity by RH1 revealed that 1) RH1 was not cytotoxic for human lymphocytes at 37 degrees C in the absence of C; 2) purified F(ab')2 fragments were equally inhibitory as whole serum; 3) pretreatment of lymphocytes with RH1 effectively inhibited their capacity to mediate ADCC, CMC, or NK, and this effect was reversible by culturing the cells overnight at 37 degrees C; 4) RH1 did not inhibit target cell binding by K cells, effector cells of ADCC, or alloimmune T cells, but did inhibit binding by NK cells; and finally, 5) the addition of RH1 to preformed lymphocyte-target conjugates in a single cell cytotoxicity assay inhibited killing of the bound target cells in all three systems without disrupting the conjugates. Collectively, these findings suggest that RH1 antiserum interacts with structures present on the surfaces of cytotoxic lymphocytes that are involved in the activation of the lytic mechanism(s) or with the actual lytic molecule or molecules themselves. Furthermore, the ability of RH1 to inhibit ADCC, CMC, and NK during the post-binding cytolytic phase of these reactions indicates that binding and cytolysis are distinct and separate events in all types of cell-mediated cytolysis.
通过用伴刀豆球蛋白A(Con A)激活的同种异体免疫人淋巴细胞对Lewis大鼠进行超免疫,制备了异种抗血清(RH1)。抗血清RH1在无补体(C)的情况下能有效抑制人抗体依赖性细胞毒性(ADCC)、细胞介导的细胞毒性(CMC)和自然杀伤(NK)。RH1的抑制作用取决于所用抗血清的稀释度以及细胞溶解过程中存在的细胞毒性淋巴细胞数量。用RH1预处理淋巴细胞或在培养中加入RH1并不抑制由Con A、植物血凝素或同种异体细胞刺激的淋巴细胞增殖;通过白细胞抑制因子产生来衡量的淋巴因子产生;抗体依赖性补体溶解;或由鼠细胞毒性T淋巴细胞介导的CMC。对RH1抑制细胞毒性机制的分析表明:1)在无补体的情况下,37℃时RH1对人淋巴细胞无细胞毒性;2)纯化的F(ab')2片段与全血清具有同等的抑制作用;3)用RH1预处理淋巴细胞可有效抑制其介导ADCC、CMC或NK的能力,且通过在37℃下将细胞培养过夜,这种作用是可逆的;4)RH1不抑制ADCC的效应细胞K细胞、同种异体免疫T细胞与靶细胞的结合,但能抑制NK细胞的结合;最后,5)在单细胞细胞毒性试验中,向预先形成的淋巴细胞 - 靶细胞结合物中加入RH1可抑制所有三种系统中结合靶细胞的杀伤,而不破坏结合物。总体而言,这些发现表明RH1抗血清与细胞毒性淋巴细胞表面存在的结构相互作用,这些结构参与裂解机制的激活,或者与实际的裂解分子本身相互作用。此外,RH1在这些反应的结合后细胞溶解阶段抑制ADCC、CMC和NK的能力表明,在所有类型的细胞介导的细胞溶解中,结合和细胞溶解是不同且分开的事件。